COVIMMUNE
DEAD

Serial Number

90025332

Owner

COVImmune Pharma LLC

Attorney

David G. Oberdick

Filing Date

Jun 29, 2020

Add to watchlist:

No watchlists yet
View on USPTO

COVIMMUNE Trademark

Serial Number: 90025332

COVIMMUNE is a trademark filed by COVImmune Pharma LLC on June 29, 2020. The trademark is classified under Class 5 (Pharmaceuticals). The application is currently no longer active.

Owner Contact Info

COVImmune Pharma LLC (5 trademarks)

6817 208th Street SW #1491
Lynnwood, WA 98046

Entity Type: 16

Trademark Details

Filing Date

June 29, 2020

Registration Date

Not Registered

Goods & Services

Pharmaceutical preparations for the treatment of immunological, viral, inflammatory, infectious autoimmune disorders; Pharmaceutical preparations for the treatment and prevention of COVID-19 (SARSCOV-2) and coronavirus; Pharmaceutical preparations and substances, used internally as liquid medicines syrup, emulsion or suspension or solids as pills or capsules or chewable tablets for the treatment and prevention of viral infections by boosting the immune system to kill viruses, bacteria, coronaviruses including COVID-19 (SARS-COV-2) and coronavirus; Pharmaceutical preparations for the prevention of COVID-19 (SARS-COV-2) and coronavirus; Pharmaceutical preparations for the treatment and prevention of COVID-19 (SARSCOV-2) and coronavirus; Pharmaceutical preparations for the treatment of infectious diseases; Pharmaceutical preparations for the treatment of COVID-19 (SARS-COV-2) and coronavirus; Pharmaceutical preparations for COVID-19 (SARSCOV-2) and coronavirus; Pharmaceutical preparations, namely, elixirs for the treatment of COVID-19 (SARS-COV-2) and coronavirus; Pharmaceutical products for treating respiratory diseases; Chemical preparations for pharmaceutical or medical purposes, namely, for COVID-19 (SARS-COV-2) and coronavirus; Inhaled pharmaceutical preparations for the treatment of COVID-19 or coronavirus respiratory diseases and disorders; Therapeutic pharmaceutical for the treatment of COVID-19 (SARS-COV-2) and coronavirus; Pharmaceutical preparations to boost, enhance, induce, or train and educate the immune system for the treatment of COVID-19 disease and immune system related diseases and disorders Dietary and nutritional supplements for therapeutic treatment to boost immune system responses against COVID-19 disease and immune related diseases and disorders; Dietary and nutritional supplements for boosting immune system responses; Pharmaceuticals, namely, immunomodulators, antivirals, antibiotics and anti-inflammatories

Filing History

ABANDONMENT NOTICE E-MAILED - FAILURE TO RESPOND
Apr 13, 2021 MAB2
ABANDONMENT - FAILURE TO RESPOND OR LATE RESPONSE
Apr 13, 2021 ABN2
NOTIFICATION OF NON-FINAL ACTION E-MAILED
Sep 30, 2020 GNRN
NON-FINAL ACTION E-MAILED
Sep 30, 2020 GNRT
NON-FINAL ACTION WRITTEN
Sep 30, 2020 CNRT
ASSIGNED TO EXAMINER
Sep 29, 2020 DOCK
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Jul 24, 2020 NWOS
NEW APPLICATION ENTERED
Jul 2, 2020 NWAP